Moderna Booster May Wane After 6 Months, Company Says
The Moderna vaccine and booster don't protect against Omicron as well as they do against the original SARS-CoV-2
ByJanuary 26, 2022 5:51 PM ESTModerna reported today the first data on how well its currently authorized vaccine and booster hold up against the, which quickly dominated new infections around the world after health experts first described the variant last November. The company also announced that it is starting to study its Omicron-specific vaccine.
In aNew England Journal of Medicine, the company’s scientists reported the results of a study involving blood samples from a small number of vaccinated participants. Antibody levels generated by Moderna’s primary two-dose regimen continued to neutralize Omicron in lab tests, but these levels were 35 times lower against Omicron than the original SARS-CoV-2, against which the vaccine was designed.Read more: TIME Health »
‘We Have to Act': Biden Calls for Tougher Gun Laws After Texas School Shooting
An anguished and angry President Joe Biden called for new restrictions on firearms Tuesday night after a gunman massacred 18 children at a Texas elementary school. “We have to act,” Biden told the nation, after years of failure to pass new laws. “When in God’s name are we going to stand up to the gun lobby?” Biden said at the White House… Read more >>
Moderna begins testing omicron-specific COVID-19 vaccine in adultsIt’s not clear whether global health authorities will order a change to the vaccine recipe in the wake of the hugely contagious omicron variant, since the original vaccines still offer good protection.
Moderna starts clinical trial of booster shot targeting omicron Covid variantThe first participant in the trial has already received a dose of the omicron-specific booster shot, according to Moderna. What’s the point? Omicron gonna have run it’s course by the time it’s done… JAB ME HARDER DADDY. MORE!!!!!
Moderna begins next phase of Omicron-specific booster trial as study finds that antibodies remain durable despite 6-fold drop over 6 monthsModerna has announced that the first participant has been dosed in the company's Phase 2 clinical trial of a coronavirus vaccine booster shot that is specific to the Omicron variant Nope....I think we are good off all these vaccines that keep coming and not working for this or that.....sounds like we're test dummies and your trying your next attempt again.......no thank you. The world didn't have this problem until airlines had huge fleets of jumbo jets making transoceanic travel easier, faster, and more affordable. The more mobile we got, the more easily these viruses have been able to spread. Now, more efficiently than at any time in human history. If everyone just got the first 2 jabs we wouldn’t need all these booster jabs. Who’s fault is that?
In a joint letter, six unions from across county sectors say booster mandate will harm staffing“Santa Clara County led the way responding to Covid, and we have done very well,” the letter states. “With these latest changes though, we’re cutting off our nose to spite our fac…
Pepsi Faces Boycott Threat Over Donation to Texas GOPPepsi is facing growing boycott calls over a $15,000 donation to the Texas Republican Party that appeared in state records three months after the state’s extreme restrictions on abortion went into effect. In other news: Pepsi will rebrand itself to MagicFiz. According to a source with direct knowledge of the matter, it is meant to signal the drinks giant’s ambition to be known for more than cola and funding politicians. Guess I’ll be buying more Pepsi! CosentinoT Any Texan drinking Pepsi should hang their heads in shame, anyway. It's gawdawful and it's not Coke or Dr. Pepper.
‘Stop panic selling’ — Bitcoin whales bag spare BTC as exchange balances fallBitcoin may be at multi-month lows, but buyer demand for BTC remains, data shows. The hype project right now is Meta2Earn 🚀 They launched $META token, market cap is growing by the day 🤑 You must see it! 🔥 The more this happens the more they got control over the market. Like whales are in better position than retail I think no one should sell their $BTC, only if they are selling it to buy $FIS. Otherwise what's the justification.
NurPhoto via Getty Images—Gerardo Vieyra/NurPhoto By January 26, 2022 5:51 PM EST M oderna reported today the first data on how well its currently authorized vaccine and booster hold up against the , which quickly dominated new infections around the world after health experts first described the variant last November. The company also announced that it is starting to study its Omicron-specific vaccine. In a New England Journal of Medicine , the company’s scientists reported the results of a study involving blood samples from a small number of vaccinated participants. Antibody levels generated by Moderna’s primary two-dose regimen continued to neutralize Omicron in lab tests, but these levels were 35 times lower against Omicron than the original SARS-CoV-2, against which the vaccine was designed. A booster dose of the vaccine—which is half of one dose of the original shot—increased antibody levels in 20 study participants to 20 times higher than levels generated after the second dose of the vaccine, therefore restoring some of the waned protection. The scientists also tested a booster at the same dose as the primary two doses in another 20 volunteers, and that booster produced antibody levels that were at least two times higher than those generated by the half-dose booster. Currently, however, the U.S. Food and Drug Administration has authorized only the half-dose booster of Moderna’s shot, based on data before Omicron emerged that the half dose elicited similar antibody levels against previous variants as another full-dose booster. Read More We Urgently Need a New National COVID-19 Response Plan These antibodies against Omicron started to wane after about six months, the company reported. After hitting a peak about a month after the booster, neutralizing antibody levels dropped 6.3 fold; even more concerning, this decline occurred more quickly than the decline against the original virus that the vaccine targeted. Such rapid waning of protection after boosting with the existing vaccine makes a strong case for potentially boosting with an Omicron-specific shot, which the company is studying. That trial will include 300 people in 24 sites across the U.S. (This week, Pfizer and BioNTech also announced that they have started testing an Omicron-specific vaccine .) Moderna’s scientists are also evaluating combination vaccines, in which they put together vaccines developed for different variants, including one that targets the original virus and one that targets Omicron. Such a cocktail approach may provide broader, more durable protection against COVID-19. More Must-Read Stories From TIME How